Reslizumab

The Basics

What is Reslizumab?

Add-on maintenance treatment of severe asthma with an eosinophilic phenotype.

Brand names for Reslizumab

Cinqair

How Reslizumab is classified

Antibodies – Monoclonal (Humanized)

Reslizumab During Pregnancy

Reslizumab pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Reslizumab while pregnant

The data on pregnancy exposure from the clinical trials are insufficient to inform on drugassociated risk. Monoclonal antibodies, such as reslizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. Reslizumab has a long half-life [see CLINICAL PHARMACOLOGY]. This should be taken into consideration. In animal reproduction studies, there was no evidence of embryo-fetal adverse developmental effects with intravenous administration of reslizumab during organogenesis to pregnant mice and rabbits at doses that produced exposures up to approximately 6 times the exposure at the maximum recommended human dose (MRHD) in mice and approximately 17 times the exposure at the MRHD in rabbits . The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Taking Reslizumab While Breastfeeding

What are recommendations for lactation if you're taking Reslizumab?

No information is available on the clinical use of reslizumab during breastfeeding. Because reslizumab is a large protein molecule with a molecular weight of 147,000, absorption by the infant is unlikely after the first few weeks postpartum, and it will probably be destroyed in the infant’s gastrointestinal tract. Until more data become available, reslizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Maternal / infant drug levels

No information is available on the clinical use of reslizumab during breastfeeding. Because reslizumab is a large protein molecule with a molecular weight of 147,000, absorption by the infant is unlikely after the first few weeks postpartum, and it will probably be destroyed in the infant’s gastrointestinal tract. Until more data become available, reslizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Possible effects of Reslizumab on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Reslizumab